Metagenomi, Inc. Common Stock
MGXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 21, 2024 | H.C. Wainwright | Mitchell Kapoor | $7.00(+112%) | $3.30 | TheFly |
| Mar 28, 2024 | Jefferies | Maury Raycrof | $22.00(+98%) | $11.09 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wells Fargo | maintain | Overweight | Aug 11, 2026 |
| Chardan Capital | maintain | Buy | Jul 7, 2026 |
| Wells Fargo | maintain | Overweight | May 12, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 19, 2025 |
| Chardan Capital | maintain | Buy | Aug 15, 2025 |
| Wells Fargo | maintain | Overweight | Aug 14, 2025 |
| Chardan Capital | maintain | Buy | May 15, 2025 |
| Wells Fargo | maintain | Overweight | May 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 3, 2025 |
| Wells Fargo | maintain | Overweight | Mar 18, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 21, 2024 |
| Chardan Capital | maintain | Buy | Nov 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 6, 2024 |
| Chardan Capital | maintain | Buy | Sep 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 21, 2024 |
| Chardan Capital | maintain | Buy | Aug 19, 2024 |
| BMO Capital | maintain | Outperform | Aug 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2024 |
| JP Morgan | downgrade | Overweight →Neutral | May 2, 2024 |
| Chardan Capital | maintain | Buy | Mar 28, 2024 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $-0.73 | $-0.55 | -$257.0K | $3.0M |
| May 11, 2026 | $-0.61 | $-0.60 | $1.2M | $5.9M |
| Mar 5, 2026 | $-0.60 | $-0.58 | $3.9M | $7.3M |
| Nov 11, 2025 | $-0.55 | $-0.60 | $8.7M | $7.8M |
| Aug 12, 2025 | $-0.54 | $-0.68 | $8.5M | $7.9M |
| May 13, 2025 | $-0.68 | $-0.62 | $4.1M | $8.3M |
| Mar 17, 2025 | $-0.63 | $-0.75 | $9.6M | $9.2M |
| Nov 13, 2024 | $-0.45 | $-0.70 | $11.5M | $6.8M |
News
MGX-001 data establish preclinical proof-of-concept in hemophilia A On track to initiate global clinical trial in 2027
EMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D.
BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) and Metagenomi (NASDAQ: MGX - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Earnings and Valuation This table compares BioMarin Pharmaceutical and
EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D.
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to a loss of $0.54 per share a year ago.